Browse diseases

…an identify SLE sub-phenotypes in a well-characterized Sudanese SLE cohort, and to explore associations with clinical manifestation…

…istered 4-8 weeks after rituximab improves clinical response in systemic lupus erythematosus (SLE) patients with high baseline serum IgA2 anti-dsDNA antibod…

…Objectives Systemic Lupus Erythematosus (SLE) exhibits high clinical and molecular complexity that may …

…Objectives Lupus nephritis (LN) presents differently across geographic regions, with highe…

…hods Observational multicenter study of patients diagnosed with SLE (EULAR/ACR 2019 criteria), treated with ANI who presented renal…

… the 2019 EULAR/ACR criteria for SLE and presenting with severe SLE-ITP(<50,000/mm 3) with at least 6 months follow-up were included. T…

…Objectives B-cell targeted therapies are increasingly used in systemic lupus erythematosus (SLE). However, real-world evidence on treatment persistence an…

…s Hydroxychloroquine (HCQ) is recommended for the management of systemic lupus erythematosus (SLE). However, substantial interindividual pharmacokinetic var…

…xpand upon previously published Phase 2 results of ianalumab in systemic lupus erythematosus (SLE) by adding post-end-of-treatment (EoT) data until end-of-s…

…, and steroid-sparing potential of anifrolumab in patients with systemic lupus erythematosus (SLE) treated at a tertiary referral center in Denmark.Methods …

…ct PO:11:285 Table 1Conclusions A small subset of patients with SLE achieve prolonged remission after a single rituximab course, wi…

…atients were younger and more likely to have moderate than mild SLE severity and more treatment types at baseline. ATT-weighted bas…